CD33 and Alzheimer disease: Recent investigations have identified mutations in AD risk genes associated with the immune response and endocytosis, such as ATP-binding cassette transporter A7, CD33, triggering receptor expressed on myeloid cells 2 (TREM2), and complement receptor 1, suggesting that innate immune dysfunction primarily involves microglia and peripheral myeloid cells [124].